186 related articles for article (PubMed ID: 35334081)
1. Bezafibrate Rescues Mitochondrial Encephalopathy in Mice via Induction of Daily Torpor and Hypometabolic State.
Lyu J; Zhao Y; Zhang N; Xu X; Zheng R; Yu W; Xin W; Yan C; Ji K
Neurotherapeutics; 2022 Apr; 19(3):994-1006. PubMed ID: 35334081
[TBL] [Abstract][Full Text] [Related]
2. Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
Franko A; Neschen S; Rozman J; Rathkolb B; Aichler M; Feuchtinger A; Brachthäuser L; Neff F; Kovarova M; Wolf E; Fuchs H; Häring HU; Peter A; Hrabě de Angelis M
Mol Metab; 2017 Mar; 6(3):256-266. PubMed ID: 28271032
[TBL] [Abstract][Full Text] [Related]
3. Effects of clofibrate and KH176 on life span and motor function in mitochondrial complex I-deficient mice.
Frambach SJCM; van de Wal MAE; van den Broek PHH; Smeitink JAM; Russel FGM; de Haas R; Schirris TJJ
Biochim Biophys Acta Mol Basis Dis; 2020 Jun; 1866(6):165727. PubMed ID: 32070771
[TBL] [Abstract][Full Text] [Related]
4. Bezafibrate attenuates acute lung injury by preserving mitochondrial dynamics equilibrium in pulmonary epithelial cells.
Song Y; Sun W; Li W; Li W
Int Immunopharmacol; 2023 Oct; 123():110751. PubMed ID: 37567013
[TBL] [Abstract][Full Text] [Related]
5. Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice.
Yatsuga S; Suomalainen A
Hum Mol Genet; 2012 Feb; 21(3):526-35. PubMed ID: 22012983
[TBL] [Abstract][Full Text] [Related]
6. Bezafibrate Improves Insulin Sensitivity and Metabolic Flexibility in STZ-Induced Diabetic Mice.
Franko A; Huypens P; Neschen S; Irmler M; Rozman J; Rathkolb B; Neff F; Prehn C; Dubois G; Baumann M; Massinger R; Gradinger D; Przemeck GK; Repp B; Aichler M; Feuchtinger A; Schommers P; Stöhr O; Sanchez-Lasheras C; Adamski J; Peter A; Prokisch H; Beckers J; Walch AK; Fuchs H; Wolf E; Schubert M; Wiesner RJ; Hrabě de Angelis M
Diabetes; 2016 Sep; 65(9):2540-52. PubMed ID: 27284107
[TBL] [Abstract][Full Text] [Related]
7. The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome.
Huang Y; Powers C; Moore V; Schafer C; Ren M; Phoon CK; James JF; Glukhov AV; Javadov S; Vaz FM; Jefferies JL; Strauss AW; Khuchua Z
Orphanet J Rare Dis; 2017 Mar; 12(1):49. PubMed ID: 28279226
[TBL] [Abstract][Full Text] [Related]
8. Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients' cells lacking its components.
Bastin J; Aubey F; Rötig A; Munnich A; Djouadi F
J Clin Endocrinol Metab; 2008 Apr; 93(4):1433-41. PubMed ID: 18211970
[TBL] [Abstract][Full Text] [Related]
9. Bezafibrate activation of PPAR drives disturbances in mitochondrial redox bioenergetics and decreases the viability of cells from patients with VLCAD deficiency.
Lund M; Andersen KG; Heaton R; Hargreaves IP; Gregersen N; Olsen RKJ
Biochim Biophys Acta Mol Basis Dis; 2021 Jun; 1867(6):166100. PubMed ID: 33549744
[TBL] [Abstract][Full Text] [Related]
10. Bezafibrate upregulates carnitine palmitoyltransferase II expression and promotes mitochondrial energy crisis dissipation in fibroblasts of patients with influenza-associated encephalopathy.
Yao M; Yao D; Yamaguchi M; Chida J; Yao D; Kido H
Mol Genet Metab; 2011 Nov; 104(3):265-72. PubMed ID: 21816645
[TBL] [Abstract][Full Text] [Related]
11. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Tenenbaum A; Motro M; Fisman EZ
Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
[TBL] [Abstract][Full Text] [Related]
12. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
[TBL] [Abstract][Full Text] [Related]
13. Osteoblastic differentiation improved by bezafibrate-induced mitochondrial biogenesis in deciduous tooth-derived pulp stem cells from a child with Leigh syndrome.
Han X; Nonaka K; Kato H; Yamaza H; Sato H; Kifune T; Hirofuji Y; Masuda K
Biochem Biophys Rep; 2019 Mar; 17():32-37. PubMed ID: 30533535
[TBL] [Abstract][Full Text] [Related]
14. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level.
Hiuge A; Tenenbaum A; Maeda N; Benderly M; Kumada M; Fisman EZ; Tanne D; Matas Z; Hibuse T; Fujita K; Nishizawa H; Adler Y; Motro M; Kihara S; Shimomura I; Behar S; Funahashi T
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):635-41. PubMed ID: 17194889
[TBL] [Abstract][Full Text] [Related]
15. Bezafibrate confers neuroprotection in the 5xFAD mouse model of Alzheimer's disease.
Lu Y; Fujioka H; Wang W; Zhu X
Biochim Biophys Acta Mol Basis Dis; 2023 Dec; 1869(8):166841. PubMed ID: 37558011
[TBL] [Abstract][Full Text] [Related]
16. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.
Fernandes-Santos C; Carneiro RE; de Souza Mendonca L; Aguila MB; Mandarim-de-Lacerda CA
Nutrition; 2009; 25(7-8):818-27. PubMed ID: 19268533
[TBL] [Abstract][Full Text] [Related]
17. A metabolic shift induced by a PPAR panagonist markedly reduces the effects of pathogenic mitochondrial tRNA mutations.
Wenz T; Wang X; Marini M; Moraes CT
J Cell Mol Med; 2011 Nov; 15(11):2317-25. PubMed ID: 21129152
[TBL] [Abstract][Full Text] [Related]
18. The peroxisome proliferator-activated receptor pan-agonist bezafibrate suppresses microvascular inflammatory responses of retinal endothelial cells and vascular endothelial growth factor production in retinal pigmented epithelial cells.
Usui-Ouchi A; Ouchi Y; Ebihara N
Int Immunopharmacol; 2017 Nov; 52():70-76. PubMed ID: 28866026
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of bezafibrate on fibroblasts of glutaric acidemia type II patients evaluated using an in vitro probe acylcarnitine assay.
Yamada K; Kobayashi H; Bo R; Purevsuren J; Mushimoto Y; Takahashi T; Hasegawa Y; Taketani T; Fukuda S; Yamaguchi S
Brain Dev; 2017 Jan; 39(1):48-57. PubMed ID: 27591119
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial complex III stabilizes complex I in the absence of NDUFS4 to provide partial activity.
Calvaruso MA; Willems P; van den Brand M; Valsecchi F; Kruse S; Palmiter R; Smeitink J; Nijtmans L
Hum Mol Genet; 2012 Jan; 21(1):115-20. PubMed ID: 21965299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
